Sweden · Who invested in Resistentia Pharmaceuticals?
Resistentia Pharmaceuticals's investors include Industrifonden, InnovationsKapital, Healthcap IX Advisor AB, GSK Venture Fund and BankInvest Biomedical Venture.
Sweden · Series C startup
Who invested in Resistentia Pharmaceuticals
One round we have observed, with the 5 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Funding summaryUpdated 26 Oct 2026
$14Mraised across 1 round since 2006, from 1 source
- Latest round
- Series C, $14MSept 2006
- Investors
- 5
The rounds
- Sept 2006Series C$14M
Industrifonden- InnovationsKapital
Healthcap IX Advisor AB- GSK Venture Fund
- BankInvest Biomedical Venture
From a historical funding record
Everyone who backed them
InnovationsKapitalInvestment firm1round
GSK Venture FundGrowth equity1round
BankInvest Biomedical VentureVC firm1round
Missing a round, or an investor who was in one? Tell us.
Quick answers about Resistentia Pharmaceuticals
How much has Resistentia Pharmaceuticals raised?
Resistentia Pharmaceuticals has raised $14M across 1 round since 2006.
When did Resistentia Pharmaceuticals last raise?
Resistentia Pharmaceuticals's most recent round was a Series C of $14M in Sept 2006.
What was Resistentia Pharmaceuticals's biggest round?
Its most recent round, $14M in Sept 2006, is also its largest on record.
Who backed Resistentia Pharmaceuticals first?
Resistentia Pharmaceuticals's first round on record, in Sept 2006, was backed by Industrifonden, InnovationsKapital and Healthcap IX Advisor AB and 2 others.
What stage is Resistentia Pharmaceuticals at?
Resistentia Pharmaceuticals's latest named round is a Series C, in Sept 2006.
Where is Resistentia Pharmaceuticals based?
Resistentia Pharmaceuticals is based in Sweden.
Companies like Resistentia Pharmaceuticals
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.